South Korean biopharmaceutical company in Jongno-gu, Seoul, part of the SK group and listed in Korea since 2020, which develops medicines for central nervous system disorders. Discovered and developed cenobamate, an antiseizure medicine sold as Xcopri in the United States and licensed to partners elsewhere, and solriamfetol for excessive sleepiness, runs its own discovery research and clinical development with a United States subsidiary and manufacturing through SK biotek, and has moved into targeted protein degradation and radiopharmaceuticals, taking a majority stake in Proteovant Therapeutics in 2023.
No hay comentarios disponibles.
Deja tu valoración & comentario